Gastrointestinal stromal tumors (GISTs) are the most common type of mesenchymal tumors found in the gastrointestinal tract of dogs and are characterized by specific cellular markers. These tumors ...

Indicators for Gleevec nonadherence were cognitive functioning, global health status score, social support, gender and others ...

By staying abreast of signs and risk factors, such as persistent indigestion, unexplained weight loss, or discomfort in the ...

Treatment with bezuclastinib plus Sutent led to safe and efficacious outcomes versus Sutent treatment alone in gastrointestinal stromal tumors.

GSK's $1 billion acquisition of IDRx includes IDRX-42, a precision therapy for GIST. Phase 1/1b trial shows 53% ORR in early ...

British pharmaceutical company GSK on Monday said it had agreed to buy a US company that specializes in the treatment of rare ...

The first major deal of JPM 2025 will give GSK a promising small molecule drug for gastrointestinal stromal tumors.

The British pharma giant announced plans to acquire IDRx, a Plymouth-based biotech working on precision treatments for ...

(RTTNews) - British drug maker GSK plc (GSK.L, GSK) Monday announced that it has signed an agreement to acquire IDRx, a Boston-based, clinical-stage biopharmaceutical company, for up to $1.15 billion ...

GSK (GSK) has agreed to acquire Boston-based IDRx for up to $1.15 billion as the British drugmaker looks to expand its gastrointestinal cancer portfolio, the companies said Monday. IDRx is behind IDRX ...

UK pharmaceutical giant GSK has confirmed that it has signed an agreement to acquire the privately-held biotechnology company ...